The Influence of Psoriasis on Type 2 Diabetes Mellitus Patient Profiles: A National Inpatient Sample Study.

BACKGROUND

Psoriasis is believed to be a common comorbidity of type 2 diabetes mellitus (T2DM). Little is known on the impact psoriasis has on T2DM patients' disease profiles.

OBJECTIVE

To assess the impact psoriasis has on T2DM patients' demographics, comorbidities, and health care outcomes.

METHODS

We retrospectively analyzed the 2017 U.S. National Inpatient Sample (NIS) database. We utilized ICD-10 codes to determine T2DM and psoriasis patients along with associated comorbidities. Continuous variables were compared by independent-sample tests and categorical variables were compared via Pearson chi-square. All analysis were conducted in IBM SPSS 25.

RESULTS

Among 7,705,988 T2DM admissions, 0.67% of them had comorbid psoriasis. T2DM psoriasis patients (64.38; SD: 12.403) were, on average, younger (64.38 vs 66.73; < .001) and white (78.7% vs 63.1%; < .001) and had increased foot ulcers (4.2% vs 3.8%; < .001), hyperglycemia (22.4% vs 21.0%; < .001), retinopathy (22.4% vs 21.0%; < .001), hypercoagulopathy (8.5% vs 6.9%; < .001), and hypertension (72.5% vs 70.4%; < .001) than T2DM patients without psoriasis. T2DM psoriasis patients spent more days in the hospital (5.49 vs 5.37; < .001), had more concurrent diagnoses (19.05 vs 16.5; < .001), less total charges ($60,596.71 vs $61,534.66; = 0.010) and had less in-hospital deaths (2.0% vs 2.7%; < .001) than T2DM patients without psoriasis.

CONCLUSIONS

The presence of comorbid psoriasis significantly impacts T2DM patients' demographics, comorbidities, and health care outcomes. These findings underscore the importance of early disease monitoring, cross-specialty collaboration, and medication monitoring in order to guide individualized management strategies and optimize patient care.